⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNY News
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
prnewswire.com
SNY
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
globenewswire.com
SNY
INTRACARE REBRANDS CLINICAL RESEARCH DIVISION AS "CAREON"
prnewswire.com
SNY
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026
globenewswire.com
SNY
JNJ
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses
globenewswire.com
SNY
Antibody Partnering Surges into 2026: Q1 Deals Top $36 Billion as Bispecifics and Discovery Platforms Drive Competition
globenewswire.com
ABBV
LLY
MRK
NVS
PFE
SNY
GILD
BMY
JNJ
UCB
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
globenewswire.com
SNY
Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
RAPT
SANG
INCY
ABBV
ARCT
AMGN
CHKP
PFE
LLY
SCLX
SNY
UCB
BIIB
NVS
VTRS
BMY
ABSI
ALEC
GSK
IONS
CLNN
ANNX
MED
GAM
VRTX
EXC
BLRX
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
globenewswire.com
SNY
Forbion Expands Global Investment Leadership with Senior Promotions and Appointment of Operating Partner
globenewswire.com
SNY
REGN
BIIB
INSM